



SolAeroMed Inc.  
120-4838 Richard Road SW  
Calgary, AB T3E 6L1 Canada

<https://www.solaeromed.com/>

SolAeroMed AGM & Shareholder Newsletter Oct 16, 2018

Hello SolAeroMed shareholders

I write to invite you to our AGM and provide an update on evolving developments at SolAeroMed (SAMi).

Our AGM will be held **Thursday November 29 from 4-5pm** at our new corporate head office located at 120-4838 Richard Rd SW, Calgary. Parking is available for your use. Once in the building follow the SolAeroMed signs to our Boardroom. Any issues on the day, please call Dr Cora Pieron for support on +1 403 689 5988. For those who can't attend in person, we offer teleconference:

Dial-in: 1-888-433-2192 Participant Code: 8587799 #

As in previous years our AGM (4-5pm) will include presentation of our year end financials, approval of our Board, etc. After a brief refreshment break we will continue with a more informal meeting (5-6pm) where we will present and discuss recent work on our drug and business development programs, and answer questions shareholders may have.

As well as continued partnership discussions and dissemination of our R&D program to academic and industry audiences, SAMi management has used the past year to reflect on our business development aspirations. We have taken advice from Key Opinion Leaders in respiratory drug development. This has led us to regroup and refocus efforts to advance S1226 in the disease indication of Cystic Fibrosis. While we have good evidence S1226 treats Asthma, the Cystic Fibrosis indication presents a more compelling business development case.

To this end, SAMi has been working closely with [Dr Mark Montgomery](#), a Calgary based clinician with international expertise in Cystic Fibrosis. Dr Montgomery will be the lead clinician in a SolAeroMed sponsored clinical trial to investigate S1226 in 12 subjects with cystic fibrosis. This proof of concept trial is designed to show safety and efficacy in treating Cystic Fibrosis. Positive trial results will be leveraged to secure development funding.

We look forward to sharing news of our CF trial and other R&D work at our upcoming AGM.

Please contact us directly to discuss any aspect of our evolving drug technology, development plans, investment or management. We look forward to seeing you at our AGM.

John Dennis  
CEO, SolAeroMed

[jdennis@solaeromed.com](mailto:jdennis@solaeromed.com)